Initial drug therapy for hypertensive patients with hyperlipidemia
Key result
Alternative step I antihypertensives preserve lipid profiles compared to traditional diuretics and beta-blockers.
Why the study?
The debate about whether traditional step I antihypertensive agents affect plasma lipids and cardiovascular risk in hypertensive patients with hyperlipidemia remains unresolved.
Do alternative step I antihypertensive agents (alpha 1-blockers, ACE inhibitors, calcium channel blockers) improve or have no effect on plasma lipids compared to traditional agents in hypertensive patients with hyperlipidemia?
Population
Hypertensive patients with hyperlipidemia
Comparison
Alternative step I antihypertensive agents vs traditional step I agents
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports metabolic-neutral choices in comorbid hypertension; leaves open need for updated RCTs.
Structured PICO
Do alternative step I antihypertensive agents (alpha 1-blockers, ACE inhibitors, calcium channel blockers) improve or have no effect on plasma lipids compared to traditional agents in hypertensive patients with hyperlipidemia?
P
Population
Hypertensive patients with hyperlipidemia
I
Intervention
Alternative step I antihypertensive agents (alpha 1-blockers, ACE inhibitors, and calcium channel blockers)
C
Comparator
Traditional step I antihypertensive agents (diuretics and beta-blockers)
O
Outcome
Effect on plasma lipidssurrogate
For hypertensive patients with hyperlipidemia, alpha 1-blockers, ACE inhibitors, and calcium channel blockers are preferred initial therapies as they do not adversely affect the lipid profile.
Cite This Study
Kannel et al. (1989) conducted a review in Hypertension and hyperlipidemia. Alternative step I antihypertensive agents (alpha 1-blockers, ACE inhibitors, calcium channel blockers) vs. Traditional step I agents (diuretics and beta-blockers) was evaluated. Alternative step I antihypertensive agents such as alpha 1-blockers, ACE inhibitors, and calcium channel blockers are recommended for patients with hyperlipidemia as they do not worsen lipid profiles.